Pelvic masses can represent various etiologies, including gynecologic and non-gynecologic conditions. As discussed in this paper, among all pathologies, intraabdominal dissemination of an extraskeletal myxoid chondrosarcoma (ESMC) presenting as a pelvic mass is a rare condition. The case is a 58-year-old woman with a history of soft tissue sarcoma who presented to the gynecologic oncology department with a pelvic mass and was operated on with the suspicion of mucinous ovarian cancer. She underwent complete cytoreductive surgery, and her final pathology was reported as ESMC. Due to several numbers of metastases shown in positron emission tomography-computed tomography, she had chemotherapy and then operated on for tumorectomy from the right leg. ESMC is a rare, aggressive soft tissue neoplasm that rarely has metastasis to the abdomen. This unique case presents a late recurrence of the disease to the pelvis, which can mimic mucinous ovarian cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jog.16235 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dietary Saccharomyces cerevisiae fermentation product improved egg quality by modulating intestinal health, ovarian function, and cecal microbiota in post-peak laying hens.
Poult Sci
March 2025
Animal Nutrition Institute, Key Laboratory of Animal Disease-Resistance Nutrition, Ministry of Agriculture and Rural Affairs, Key Laboratory of Sichuan Province, Sichuan Agricultural University, Chengdu, 611130, PR China. Electronic address:
Saccharomyces cerevisiae fermentation product (SCFP), a postbiotic feed additive, has potential to improve animal growth and productivity. However, its effects on post-peak laying hens have not been thoroughly investigated. Therefore, this study aimed to explore the effects of SCFP on production, egg quality, intestinal health, ovarian function, and cecal microbiota in post-peak laying hens.
View Article and Find Full Text PDFCompound cancer with small cell carcinoma and mucinous adenocarcinoma of the ovary: a case report and literature review.
Front Oncol
February 2025
Department of Obstetrics and Gynecology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Primary small cell carcinoma of the ovary is an extremely rare and highly malignant ovarian malignancy. The tissue origin of this type of cancer is still unclear, and it is characterized by rapid progression and a discouraging prognosis. The clinical presentation of small cell carcinoma of the ovary lacks specificity, and there are currently no effective treatment options available.
View Article and Find Full Text PDFThe Role of CA-125 in the Management of Ovarian Cancer: A Systematic Review.
Cancer Rep (Hoboken)
March 2025
Department of Epidemiology and Biostatistics, School of Health, Social Determinants of Health Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Background: Ovarian cancer is frequently occurring and fatal for women. CA-125 is important in the screening, diagnosis, and treatment of ovarian cancer. This review study was conducted to explore the influence of CA-125 in addressing ovarian cancer.
View Article and Find Full Text PDFControversies in the management of mucinous ovarian tumors.
Int J Gynecol Cancer
February 2025
Institut Gustave Roussy, Gyneco-Oncology Unit, Medical Oncology Department, Villejuif, France; Institut Gustave Roussy,INSERM UMR981, Villejuif, France. Electronic address:
Mucinous ovarian carcinoma (MOC) is a rare subtype of epithelial ovarian cancer, comprising less than 5% of all cases, and distinguished by its unique molecular, histologic, and clinical features. Its rarity and marked differences from other ovarian cancer subtypes have led to significant controversies regarding its diagnosis, surgical strategies, and systemic therapies. Accurate differentiation between primary and metastatic MOCs remains a critical challenge because of their overlapping features with gastrointestinal cancers, often leading to misclassification.
View Article and Find Full Text PDFImpact of lymphadenectomy rates in the quality assurance program in early ovarian cancer of the AGO Study Group - Real-world observations.
Eur J Surg Oncol
February 2025
Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany.
Objectives: The German quality assurance program (QS-Ovar) representatively documents treatment and survival for patients with the initial diagnosis of primary ovarian cancer in the third quarters of 2004, 2008, 2012, 2016, and 2021. We evaluate lymphadenectomy (LNE) rates in dependence on histologic subtype and outcome for early ovarian cancer FIGO I.
Methods: Therapy quality was defined according to national guidelines.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!